Be Bio
PrivateLast Round
Series C
Jan 15, 2025
Total Funding Raised
$356M
Company Overview
Be Biopharma, Inc. is a clinical-stage biotechnology company that operates as a developer of engineered B Cell Medicines (BCMs). The company's mission is to create a new class of cellular therapies to treat a range of serious conditions, including genetic diseases, cancer, and autoimmune disorders. By engineering B cells, which are natural protein factories, Be Bio aims to produce durable and re-dosable treatments that can deliver therapeutic proteins at constant levels for extended periods. The company's lead programs include BE-101 for Hemophilia B and BE-102 for Hypophosphatasia. Founded in October 2020, Be Bio is backed by prominent venture capital firms and pharmaceutical companies, including ARCH Venture Partners, Atlas Venture, and RA Capital Management.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Be Bio Comps
Public and private peers based on sector, stage, and business model.
Be Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 15, 2025 | ||||
| Early Funding | Oct 22, 2024 | ||||
| Series B | Apr 14, 2022 | ||||
| Series A | Oct 22, 2020 |
Key People
Founding team and executive leadership
Be Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Series C, Early Funding, Series A |
| Dean Capital Investments Management | Series B |
| ARCH Venture Partners | Series C |
| ARCH Venture Partners | Series C, Early Funding, Series B |
| Nextech Venture | Series C |
| Alta Administration | Series B |
| Atlas Venture | Series B, Series C, Early Funding, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 15, 2025
Therapeutic programs have advanced into human trials.
- Jan 15, 2025
$92M round completed.
Be Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Be Bio's valuation, stock price, and market status.
